Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Sold by BNP Paribas Financial Markets

BNP Paribas Financial Markets decreased its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 60.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,964 shares of the company's stock after selling 57,502 shares during the period. BNP Paribas Financial Markets owned 0.08% of Amphastar Pharmaceuticals worth $1,372,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Barclays PLC raised its position in shares of Amphastar Pharmaceuticals by 53.3% in the third quarter. Barclays PLC now owns 74,456 shares of the company's stock valued at $3,613,000 after buying an additional 25,878 shares in the last quarter. Arkadios Wealth Advisors increased its position in shares of Amphastar Pharmaceuticals by 5.2% during the fourth quarter. Arkadios Wealth Advisors now owns 27,964 shares of the company's stock valued at $1,038,000 after acquiring an additional 1,379 shares during the last quarter. Dakota Wealth Management grew its holdings in Amphastar Pharmaceuticals by 31.7% during the fourth quarter. Dakota Wealth Management now owns 5,486 shares of the company's stock valued at $204,000 after purchasing an additional 1,322 shares during the period. KBC Group NV boosted its holdings in shares of Amphastar Pharmaceuticals by 43.1% in the fourth quarter. KBC Group NV now owns 2,159 shares of the company's stock worth $80,000 after acquiring an additional 650 shares during the period. Finally, Pacer Advisors Inc. boosted its stake in Amphastar Pharmaceuticals by 51,977.4% during the fourth quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company's stock valued at $50,139,000 after buying an additional 1,347,775 shares during the period. Institutional investors own 65.09% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on AMPH. Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, April 10th. JPMorgan Chase & Co. reissued a "neutral" rating and issued a $30.00 price target (down from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Piper Sandler decreased their price objective on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a report on Friday, March 21st. Finally, Wells Fargo & Company cut their price objective on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a research report on Thursday, May 8th. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $32.33.

Insider Activity

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the firm's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the transaction, the chief financial officer now owns 97,363 shares of the company's stock, valued at approximately $2,681,377.02. This trade represents a 4.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders have sold 5,231 shares of company stock worth $142,752. Corporate insiders own 27.50% of the company's stock.

Amphastar Pharmaceuticals Trading Up 1.1%

Shares of NASDAQ:AMPH traded up $0.27 during trading on Friday, reaching $24.47. 548,566 shares of the company were exchanged, compared to its average volume of 481,064. The firm has a market capitalization of $1.16 billion, a PE ratio of 8.16, a P/E/G ratio of 2.19 and a beta of 0.78. The business's fifty day simple moving average is $25.20 and its 200-day simple moving average is $32.82. Amphastar Pharmaceuticals, Inc. has a 12-month low of $22.64 and a 12-month high of $53.96. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.